[{"id":"2ad2c325-cb2d-4eac-988b-e223d359b314","acronym":"","url":"https://clinicaltrials.gov/study/NCT03203005","created_at":"2021-06-30T14:53:18.228Z","updated_at":"2024-07-02T16:36:50.444Z","phase":"Phase 1/2","brief_title":"IMA970A Plus CV8102 in Very Early, Early and Intermediate Stage Hepatocellular Carcinoma Patients","source_id_and_acronym":"NCT03203005","lead_sponsor":"National Cancer Institute, Naples","biomarkers":" HLA-A","pipe":" | ","alterations":" HLA-A*02 • HLA-A*24","tags":["HLA-A"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HLA-A*02 • HLA-A*24"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • CV8102 • Hepavac (IMA970A) • cyclophosphamide intravenous"],"overall_status":"Completed","enrollment":" Enrollment 22","initiation":"Initiation: 09/18/2017","start_date":" 09/18/2017","primary_txt":" Primary completion: 12/20/2019","primary_completion_date":" 12/20/2019","study_txt":" Completion: 12/20/2019","study_completion_date":" 12/20/2019","last_update_posted":"2020-02-05"}]